PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gonadorelin→

Gonadorelin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
33515-09-2
Molecular formula
C55H75N17O13
Molecular weight
1182.31 g/mol
Drug class
Gonadotropin-releasing hormone (GnRH) analoguegonadotropin secretagogue
Mechanism of action
Binds to and activates pituitary GnRH receptors, stimulating synthesis and release of luteinising hormone (LH) and follicle-stimulating hormone (FSH). The response depends on the dose and pattern of administration.
Indications / reported uses
  • Diagnostic assessment of pituitary gonadotroph function in selected endocrine evaluations.
  • Veterinary use to induce LH release and ovulation or manage selected reproductive disorders, according to the authorised species and product.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gonadotropin-releasing-hormone-analog · https://www.ema.europa.eu/en/documents/mrl-report/gonadotrophin-releasing-hormone-gonadorelin-summary-report-committee-veterinary-medicinal-products_en.pdf

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Gonadorelin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gonadorelin Permitted Daily Exposure (PDE) report (the Gonadorelin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gonadorelin Occupational Exposure Limit (OEL) report (the Gonadorelin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.